BridgeWise Mid Cap Allocations
Smart Portfolio
💊 $SRPT (Sarepta Therapeutics Inc)@MidCapDiverse October Highlight With October drawing to a close, one stock from our portfolio stands out as a clear leader. Sarepta Therapeutics, Inc. delivered a strong October, with its stock climbing from 19.32 USD on October 1 to 23.45 USD by October 29, a gain of 21.37%. The jump was fueled by a standout Q2 financial report: 📈 Revenue surged 68.4% to 611.09M USD 💰 Net income soared to 196.89M USD 💹 EPS spiked 2,663.8% year-over-year Sarepta’s operational efficiency shone, with the EBITDA margin rising to 20.69% and the net income margin hitting 32.2%. This strong performance has led it to the top of the P/L column in the MidCapDiverse portfolio at nearly 28%. Sarepta specializes in RNA-targeted therapeutics and gene therapies that directly address rare neuromuscular diseases such as Duchenne muscular dystrophy. Its RNA-targeted drugs, particularly exon-skipping therapies, are designed to help cells bypass faulty genetic instructions at the RNA level — enabling the production of functional proteins that patients’ bodies otherwise struggle to make. On the balance sheet front, Sarepta maintains solid equity growth and healthy cash flow, supporting ongoing R&D. The company’s technical momentum remains positive, with strong stock gains and neutral sentiment indicators, suggesting continued investor confidence in its innovative pipeline. 📊 Poll: What’s your view on gene therapy stocks?
🚀 Bullish
100.00%
⚖️ Neutral
100.00%
📉 Bearish
100.00%
🤔 Watching
100.00%
null
.